Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:9817509rdf:typepubmed:Citationlld:pubmed
pubmed-article:9817509lifeskim:mentionsumls-concept:C0237401lld:lifeskim
pubmed-article:9817509lifeskim:mentionsumls-concept:C0599755lld:lifeskim
pubmed-article:9817509lifeskim:mentionsumls-concept:C0026565lld:lifeskim
pubmed-article:9817509lifeskim:mentionsumls-concept:C0205470lld:lifeskim
pubmed-article:9817509lifeskim:mentionsumls-concept:C0392747lld:lifeskim
pubmed-article:9817509lifeskim:mentionsumls-concept:C0205210lld:lifeskim
pubmed-article:9817509lifeskim:mentionsumls-concept:C0018387lld:lifeskim
pubmed-article:9817509lifeskim:mentionsumls-concept:C2348519lld:lifeskim
pubmed-article:9817509pubmed:issue4lld:pubmed
pubmed-article:9817509pubmed:dateCreated1999-1-20lld:pubmed
pubmed-article:9817509pubmed:abstractTextClinical symptoms and immunological changes associated with HIV-2 infection were studied in a cohort of police officers in Guinea-Bissau. HIV-related symptoms were classified according to the WHO clinical staging system. The inclusion period was from January 1990 to January 1997, and among 2637 subjects included (90.7%M, 9.3%F), the prevalence of HIV-1, HIV-2 and dual reactivity to both HIV-1 and HIV-2 was 0.9%, 9.7% and 0.5%, respectively. Weight loss > 10%, diarrhoea or fever > 1 month, generalized lymphadenopathy and generalized pruritic dermatitis were significantly associated with HIV-2 infection as well as suppression of CD4 cells as compared with HIV-negative controls. Females had significantly higher CD4 cell counts than males, both among HIV-negative and HIV-2-positive asymptomatic individuals. The mortality rates/100 person-years (p.y.) were 0.4 in HIV-negative and 2.6 in HIV-2-positive subjects, giving an age-adjusted mortality rate ratio of 6.6 (95% CI, 4.0-10.9; p < 0.001). The mortality rate among HIV-2-infected individuals varied considerably in different stages of the WHO clinical staging system; 1.7 and 8.0/100 p.y. in stage 1 and 3, respectively.lld:pubmed
pubmed-article:9817509pubmed:languageenglld:pubmed
pubmed-article:9817509pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9817509pubmed:citationSubsetIMlld:pubmed
pubmed-article:9817509pubmed:statusMEDLINElld:pubmed
pubmed-article:9817509pubmed:issn0036-5548lld:pubmed
pubmed-article:9817509pubmed:authorpubmed-author:AnderssonSSlld:pubmed
pubmed-article:9817509pubmed:authorpubmed-author:BiberfeldGGlld:pubmed
pubmed-article:9817509pubmed:authorpubmed-author:NauclérAAlld:pubmed
pubmed-article:9817509pubmed:authorpubmed-author:NorrgrenHHlld:pubmed
pubmed-article:9817509pubmed:authorpubmed-author:DiasFFlld:pubmed
pubmed-article:9817509pubmed:authorpubmed-author:Da SilvaZ JZJlld:pubmed
pubmed-article:9817509pubmed:authorpubmed-author:BiagueA JAJlld:pubmed
pubmed-article:9817509pubmed:issnTypePrintlld:pubmed
pubmed-article:9817509pubmed:volume30lld:pubmed
pubmed-article:9817509pubmed:ownerNLMlld:pubmed
pubmed-article:9817509pubmed:authorsCompleteYlld:pubmed
pubmed-article:9817509pubmed:pagination323-9lld:pubmed
pubmed-article:9817509pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:9817509pubmed:meshHeadingpubmed-meshheading:9817509-...lld:pubmed
pubmed-article:9817509pubmed:meshHeadingpubmed-meshheading:9817509-...lld:pubmed
pubmed-article:9817509pubmed:meshHeadingpubmed-meshheading:9817509-...lld:pubmed
pubmed-article:9817509pubmed:meshHeadingpubmed-meshheading:9817509-...lld:pubmed
pubmed-article:9817509pubmed:meshHeadingpubmed-meshheading:9817509-...lld:pubmed
pubmed-article:9817509pubmed:meshHeadingpubmed-meshheading:9817509-...lld:pubmed
pubmed-article:9817509pubmed:meshHeadingpubmed-meshheading:9817509-...lld:pubmed
pubmed-article:9817509pubmed:meshHeadingpubmed-meshheading:9817509-...lld:pubmed
pubmed-article:9817509pubmed:meshHeadingpubmed-meshheading:9817509-...lld:pubmed
pubmed-article:9817509pubmed:meshHeadingpubmed-meshheading:9817509-...lld:pubmed
pubmed-article:9817509pubmed:meshHeadingpubmed-meshheading:9817509-...lld:pubmed
pubmed-article:9817509pubmed:meshHeadingpubmed-meshheading:9817509-...lld:pubmed
pubmed-article:9817509pubmed:meshHeadingpubmed-meshheading:9817509-...lld:pubmed
pubmed-article:9817509pubmed:meshHeadingpubmed-meshheading:9817509-...lld:pubmed
pubmed-article:9817509pubmed:meshHeadingpubmed-meshheading:9817509-...lld:pubmed
pubmed-article:9817509pubmed:meshHeadingpubmed-meshheading:9817509-...lld:pubmed
pubmed-article:9817509pubmed:meshHeadingpubmed-meshheading:9817509-...lld:pubmed
pubmed-article:9817509pubmed:meshHeadingpubmed-meshheading:9817509-...lld:pubmed
pubmed-article:9817509pubmed:meshHeadingpubmed-meshheading:9817509-...lld:pubmed
pubmed-article:9817509pubmed:meshHeadingpubmed-meshheading:9817509-...lld:pubmed
pubmed-article:9817509pubmed:year1998lld:pubmed
pubmed-article:9817509pubmed:articleTitleClinical features, immunological changes and mortality in a cohort of HIV-2-infected individuals in Bissau, Guinea-Bissau.lld:pubmed
pubmed-article:9817509pubmed:affiliationNational Public Health Laboratory, Bissau, Guinea-Bissau, Guinea-Bissau.lld:pubmed
pubmed-article:9817509pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:9817509pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:9817509lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:9817509lld:pubmed